RFL (Rafael Holdings) Valuation Rank


RFL Rafael Holdings Inc RFL
48 GF Score
Price $3.03
GF Value $1.35
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Rafael Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Rafael Holdings Valuation Rank Related Terms

RFL
48GF Score
Rafael Holdings Inc RFL
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rafael Holdings (RFL) Overvalued in 2026?

Based on GuruFocus' analysis, Rafael Holdings stock appears to be overvalued. The current stock price of $3.03 is trading 124.4% above its estimated GF Value™ of $1.35. GuruFocus considers Rafael Holdings to be Significantly Overvalued.

Key valuation signals for RFL:

  • Valuation Rank:
  • GF Value™: $1.35 vs. price of $3.03 (124.4% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the RFL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rafael Holdings Business Description

Address 520 Broad Street, Newark, NJ, USA, 07102
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
48GF Score

Get the complete analysis for RFL

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.03
Price
$1.35
GF Value